Diffusion Pharmaceuticals

130 articles with Diffusion Pharmaceuticals

• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

  9/11/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Robert Cobuzzi, Ph.D., chief executive officer, will present a corporate overview of the Company on Tuesday, September 15th

• 

  BioSpace Movers & Shakers, Sept. 11

  9/11/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.

• Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical TrialTwenty-four patient Phase 1b safety and tolerability study initiated in Romania

  9/10/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”) today announced dosing of the first two patients in the Company’s open-label Phase 1b lead-in trial of its novel, oxygen-enhancing therapeutic, trans sodium crocetinate (“TSC”), in 24 hospitalized COVID-19 patients. In addition to evaluating the safety and tolerability of TSC, this trial will collect preliminary data on TSC’s effects on arterial blood oxygenat

• Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

  9/8/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who has served as a member of the Company’s Board of Directors since January 2020, will succeed David G. Kalergis as President and Chief Executive Officer effective immediately.

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of DirectorsRomanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial

  9/1/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the appointment of Jane H. Hollingsworth to its board of directors, effective immediately.

• Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business UpdateContinues global clinical development of TSC for the treatment of COVID-19

  8/10/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today reported financial results for the three and six months ended June 30, 2020 and provided a business update. Highlights from the second quarter of 2020 and recent w

• Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC

  7/27/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced receipt of guidance from the U.S. Food and Drug Administration (FDA) on the Company’s recently-filed Investigational New Drug (IND) application

• Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC

  7/7/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for trans sodium crocetinate (TSC) in COVID-19 patients

• Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price RequirementShare price exceeds $1 at closing for 10 consecutive trading days

  6/1/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”) announces that on May 29, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing standard and the matter is now closed. The Company had previously been notified by Nasdaq on December 11, 20

• 

  Biopharma Update on the Novel Coronavirus: May 27

  5/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.

• Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program

  5/26/2020

  First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpoints

• Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market

  5/20/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body's ability to deliver oxygen to the areas where it is needed most, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with certain institutional and accredited investors of 11,428,572

• Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases

  5/20/2020

  Planned study features noted principal investigator, regulatory flexibility, and immediate availability of patients

• Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  5/18/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors to purchase, in a registered direct o

• Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

  5/11/2020

  Expands TSC development to include COVID-19 related Acute Respiratory Distress Syndrome as enrollment in Phase 2 on-ambulance stroke trial is delayed

• Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS

  5/5/2020

  Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles Simultaneous patient enrollment planned in both the U.S. and Eastern Europe to speed time to data readout CHARLOTTESVILLE, Va., May 05, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to del

• Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19

  4/27/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the pre-IND submission to the U.S. Food and Drug Administration (

• Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the CoronavirusOvertaxed healthcare systems will delay enrollment in some geographic locations

  3/24/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it expect delays in enrollment in the Company’s ambulance-based PHAST-TSC phase 2 clinical trial in acute stroke due to the coronavirus.